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Radionuclides
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The last decade has seen rapid growth in the use of theranostic radionuclides for the
treatment and imaging of a wide range of cancers. Radionuclide therapy and imaging
rely on a radiolabeled vector to specifically target cancer cells. Radionuclides that emit
β particles have thus far dominated the field of targeted radionuclide therapy (TRT),
mainly because the longer range (µm–mm track length) of these particles offsets the
heterogeneous expression of the molecular target. Shorter range (nm–µm track length)
α- and Auger electron (AE)-emitting radionuclides on the other hand provide high
ionization densities at the site of decay which could overcome much of the toxicity
associated with β-emitters. Given that there is a growing body of evidence that other
sensitive sites besides the DNA, such as the cell membrane and mitochondria, could
be critical targets in TRT, improved techniques in detecting the subcellular distribution
of these radionuclides are necessary, especially since many β-emitting radionuclides
also emit AE. The successful development of TRT agents capable of homing to targets
with subcellular precision demands the parallel development of quantitative assays for
evaluation of spatial distribution of radionuclides in the nm–µm range. In this review, the
status of research directed at subcellular targeting of radionuclide theranostics and the
methods for imaging and quantification of radionuclide localization at the nanoscale are
described.
Keywords: subcellular targeting, radioimmunotherapy, targeted radionuclide therapy, radiopharmaceuticals,
cancer, dosimetry
INTRODUCTION
The capacity of a pharmacon to selectively find its biological target is an important determinant
of its usefulness in clinical medicine. Many pharmacologically active substances have intracellular
molecular targets that reside in organelles (D’Souza and Weissig, 2009). Carriers that selectively
target these subcellular structures have been investigated extensively, and include micro- or
nanoparticulate drug carriers, liposomal formulations, macromolecular drug conjugates, and
chemically modified proteins (Rajendran et al., 2010). One field where subcellular targeting
has been relatively unexplored, but has the potential to make a profound impact, is targeted
radionuclide therapy (TRT).
Targeted radionuclide therapy is a treatment modality that encompasses the use of
radionuclide-conjugated cancer-specific vectors, such as small molecules, peptides, antibodies, and
nanoparticles, to selectively deliver radiation to the tumor. TRT compounds are often designed as
theranostic agents; so that, when coupled to suitable radionuclides, they can be used for positron
emission tomography (PET) or single-photon emission computed tomography (SPECT). A large
Frontiers in Pharmacology | www.frontiersin.org 1 September 2018 | Volume 9 | Article 996
fphar-09-00996 August 31, 2018 Time: 18:35 # 2
Bavelaar et al. Subcellular Targeting of Theranostic Radionuclides
body of evidence, accumulated over several decades, has
established TRT as an effective anticancer strategy (Jackson
et al., 2013; Pouget et al., 2015; Aghevlian et al., 2017).
Prominent examples include treatments for lymphoma [yttrium-
90 (90Y)-ibritumomab tiuxetan], neuroblastoma [iodine-131
(131I)-MIBG], and prostate cancer [radium-223 dichloride
(223RaCl2)] (Larson et al., 2015; Gill et al., 2017). The success
of the NETTER-1 trial with lutetium-177 (177Lu)-DOTATATE in
patients with midgut neuroendocrine tumors (Strosberg et al.,
2017), and the promising results of 177Lu-prostate specific-
membrane antigen (177Lu-PSMA) ligand treatments in patients
with prostate cancer (von Eyben et al., 2018) have given
this field further positive momentum. However, challenges
remain, including heterogeneous expression of molecular targets
relevant to TRT, sub-optimal tumor delivery or penetration,
and radioresistance. The latter characteristic means that for
many solid tumors a five- to 10-fold higher radiation absorbed
dose must be achieved for tumor eradication compared
to hematological malignancies (Pouget et al., 2011). Several
strategies have been tested to increase the anticancer efficacy
of TRT. One option is to design radiopharmaceuticals that
specifically target radiosensitive organelles to increase the
probability of cell kill (Aghevlian et al., 2017). Typically,
radionuclides that emit short-range Auger electrons (AEs) are
used in this context due to their highly localized dose-deposition.
It is notable that the decay of several widely-used β-emitting
therapeutic radionuclides includes a substantial AE contribution,
thus generating both local and distant radiotoxic effects due
to AE and β-electrons, respectively (Falzone et al., 2015).
Subcellular targeting of these radionuclides may be advantageous
since the AE cause local damage to the targeted compartment.
Even for high energy, short range α-emitters, the effects of
subcellular localization may influence the cytotoxicity of short-
range daughter products. Therefore, a better understanding
of the subcellular distribution of radionuclides may lead to
optimization of TRT. Over the past decade, several strategies
for subcellular delivery have been tested, including nuclear,
mitochondrial, cell membrane, and lysosomal delivery. This
review is focused on the relationship between the track path-
length of radionuclide emissions, subcellular targeting, and
radiation-induced cell kill. To understand the importance of
subcellular targeting in TRT, basic radiobiological concepts will
be reviewed. The methods used to investigate the subcellular
distribution of radionuclides are considered and the results of
pre-clinical and clinical studies aimed at exploring organelle-




Radionuclides are unstable atomic nuclei that release energy
by emission of particulate radiation in the form of α-particles,
β-particles, or AE, and by electromagnetic radiation in the form
of X- or γ-rays. Their action is described by their linear energy
transfer (LET), which is the amount of energy that an ionizing
particle deposits in matter per unit distance. Radionuclides are
used extensively for diagnostic and therapeutic purposes in
cancer treatment. β electron-emitting radionuclides, also known
as β-emitters, have historically been the most commonly used
class of radionuclides in the therapeutic setting. β-emitters release
electrons of mean energy ranging from about 0.2–1.0 MeV,
resulting in a long track path-length with a continuous-slowing-
down-approximation (CSDA) range in water of up to 12 mm. As
a consequence, the LET of β-emitters is low (<1 keV/µm; Kassis,
2004). With the clinical development of 223RaCl2 over the last
decade, α-emitters are now being studied intensively for various
applications. α-emitters decay by releasing helium nuclei, known
as α-particles, with energy ranging from 5 to 9 MeV over an
intermediate track path-length in water (50–100 µm), resulting
in high LET to exposed cells (50–230 keV/µm; Pouget et al.,
2015). AEs, which are of particular interest in the context of
subcellular targeting, are ejected from electron shells following
a process called internal atomic ionization. This process is a
result of nuclear decay modes that interact strongly with atomic
shells, such as electron capture or internal conversion. Most AEs
have a low energy (<5 keV) and very limited tissue penetration
depth (< 1 µm), leading to a high LET (4–26 keV/µm; Lee
et al., 2015). It is important to note that most radionuclides emit
multiple types of radiation. For example, 177Lu, which is used in
the treatment of somatostatin receptor positive tumors (177Lu-
DOTATATE) and in the prostate cancer-targeting agent, 177Lu-
PSMA, decays by emission of both β-electrons and AE (Hindié
et al., 2016). Furthermore, photons emitted during the decay can
be detected by SPECT, which makes it a suitable radionuclide
for combined therapy and diagnosis (Uribe et al., 2017). Table 1
summarizes the decay properties of several radionuclides that
have been used or considered for diagnostics and therapy in the
clinic (Eckerman and Endo, 2007; Falzone et al., 2015).
To illustrate how the different ranges of these particles
translate to successful subcellular targeting, the associated
absorbed dose per cumulated activity for different radionuclides
are compared in Figure 1. Most of the energy associated with
AE is deposited over a distance < 1 µm from the point of
decay. Examples include gallium-67 (67Ga), technetium-99m
(99mTc), indium-111 (111In), and iodine-123 (123I) (Figure 1A).
A sinusoidal energy-deposition profile is seen for all AE-emitting
radionuclides in the first 10µm from the point of decay. A similar
profile, albeit less pronounced, is also present for β-emitters, i.e.,
copper-67 (67Cu), samarium-153 (153Sm), terbium-161 (161Tb),
and 177Lu, as they also emit AE. When considering the absorbed
dose received by targeted organelles within a cell, it can be
seen from Figures 1B–D that AE-emitters are significantly
more effective than β-emitters 67Cu and 177Lu for organelles
such as the mitochondria. It is noteworthy that the β-emitting
radionuclide 161Tb deposits a higher dose over the distance
considered than the other β-electron-emitting radionuclides,
which is partly due to release of AE in the decay cascade.
β-emitters, on the other hand, deposit a greater absorbed dose
than AE-emitters when the target volume is larger than an
average cell (∼20 µm in diameter). α-emitters, such as astatine-
211 (211At), deliver the highest dose within the range considered.
At dimensions larger than a standard cell diameter (20 µm),
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TABLE 1 | Decay properties of several radionuclides used in diagnostics and therapy.
Per decay 67Cu(β) 67Ga(A) 99mTc(A) 111In(A) 123I∗(A) 153Sm(β) 161Tb(β) 177Lu(β) 211At(α)
Half- life (days); Decay mode 2.58; β− 3.26; ECf 0.25; ITg β− 2.80; EC 0.55; EC 1.93; β− 6.89; β− 6.65; β− 0.30; EC α
Yield of AEa and CKb e− 0.56 4.96 4.41 7.43 13.7 6.58 11.0 1.12 6.53
Yield of IEc e− 0.15 0.34 1.10 0.16 0.16 0.81 1.42 0.15 3.85E-04
Yield of X-rays 0.78 6.87 5.58 9.50 15.8 8.30 13.0 1.37 7.73
Yield of γ rays 0.73 0.87 0.89 1.85 0.86 0.37 0.53 0.18 1.38E-02
Yield of β+ or β− 1.00 – 3.70E-05 – – 1.00 1.00 1.00 –
Yield of α – – – – – – – – 1.00
Yield of α recoils – – – – – – – – 1.00
Total γ- and X-ray energy (keV/nt) 115 160 127 386 173 64.3 36.5 35.1 44.8
Total β+ or β− energy (keV/nt) 136 – 4.20E-03 – – 224 154 133 –
Total IE e− energy (keV/nt) 13.7 29.7 15.2 27.9 21.0 40.3 39.3 13.5 0.27
Total AE and CK energy (keV/nt) 0.75 6.64 0.94 6.88 7.23 6.02 8.94 1.13 5.86
Total α energy (keV/nt) – – – – – – – – 6.78E+03
Total α recoil energy (keV/nt) – – – – – – – – 131
Total energy released (keV/nt) 266 196 1.43 441 201 334 239 183 6.96E+03
(p/e)d ratio 0.76 4.50 7.90 11.1 6.10 0.24 0.18 0.24 6.48E-03
Yield is the number of radiative species released per decay (/nt). Source: Falzone et al. (2015). Adapted and reproduced with permission from the Journal of Nuclear
Medicine. Copyright: Society of Nuclear Medicine and Molecular Imaging.
A: SPECT; B: PET; ∗123 I decays to 123Te and 123mTe, with half-lives too long to play a role in TRT. ˆ211At decays to 211Po (T1/2 = 0.516 s) and 207Bi (T1/2 = 31.55 y),
radiation from the latter is excluded due to its long half-life.
aAuger electron; bCoster–Kronig electron; c internal conversion electron; dratio of penetrating to non-penetrating ionizing radiation; especific activity; felectron capture;
g isomeric transition.




As a result of their low LET and long track-length, β-electrons
cause sparse ionizations over tens to hundreds of cell diameters.
The range of β-electrons means that a vector carrying
radionuclides of this type may not need to reach each and
every tumor cell to achieve the desired anti-tumor effect as non-
targeted cells may be damaged through the “crossfire effect”
(Pouget et al., 2015). Thus, success of this type of therapy is not
critically dependent on homogeneous radionuclide distribution
within a tumor. On the downside, this also means that nearby
normal tissue may receive a toxic absorbed dose, thus limiting the
administered amount of radioactivity and, therefore, the tumor
absorbed radiation dose that can be safely achieved. Furthermore,
the low-density ionizations caused by β-electrons may not be
sufficient to cause cell death, especially in radioresistant cells. In
contrast, α-particles travel a much shorter distance (roughly 5–10
cell diameters) and, in contrast to β-emitters, are densely ionizing
and cause complex, irreparable DNA damage in the cells they
traverse. An intriguing phenomenon for TRT with α-emitters
is dissociation of the radionuclide from the chelating group
upon decay, either due to the altered coordination chemistry
of the daughter elements in the decay cascade or the high
recoil energy generated upon the emission of α-particles. The
recoiled daughter nuclei are often themselves α-emitters and this
phenomenon may lead to toxicity or desired cytotoxic effect at
the daughter decay sites as some daughter nuclei are long-lived
and able to move away from the targeted cells before they decay
(Dekempeneer et al., 2016; Ackerman et al., 2018). Furthermore,
these recoiled daughter nuclei have a LET that is at least 10
times greater than the ejected α-particles and may contribute
significantly to ionization events in the immediate vicinity of
the decay site (Kozempel et al., 2018). The extreme density
of ionization events caused by α-emitters and their daughter
nuclides, which are short-lived and decay close to the decay site
of the parent nuclide, may be exploited for therapeutic gain in
TRT if directed at specific radiosensitive cellular compartments.
AE cause dense ionizations, but only on a nanometer scale. The
result is that the radionuclides are relatively harmless unless they
are in close proximity to a targeted radiosensitive subcellular
structure (Falzone et al., 2015). This characteristic can be highly
advantageous in reducing the side effects of TRT as, unlike α-
or β-particles, non-targeted neighboring cells remain unaffected
by radiation. For the radiopharmaceutical to be effective in the
targeted cell, however, precise subcellular targeting is essential
for the radiopharmaceutical to achieve its optimal anti-tumor
effect. As many β-emitters also emit AE, their anti-tumor effect
in the targeted cells could be enhanced if precise subcellular
targeting is applied to β-emitters. An example of this is 161Tb,
a β-emitter that emits a comparable number of AE to many
classical AE-emitters.
Besides targeted radiation effects, TRT can also induce non-
targeted effects, which have been hypothesized to result from
the production of various apoptotic factors, cytokines, and
reactive oxygen species (ROS). This is known as the “bystander
effect,” causing perturbations in unirradiated cells which are
close to irradiated cells. The bystander response is observed for
both high-LET (α-particles and AE) and low-LET (β-electrons)
radiation (Boyd et al., 2006). The topic of the bystander effect has
been recently reviewed (Brady et al., 2013; Pouget et al., 2015).
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FIGURE 1 | Energy and dose-deposition of various radionuclides. Energy and dose-deposition profiles for various radionuclides in spherical water volumes up to
100 µm in diameter. Calculations for electrons are based on a Monte Carlo method described by Falzone et al. (2017). Energy deposition by α-particles and recoiling
daughter nuclei is derived from the NIST (Berger et al., 2005) and SRIM (Ziegler et al., 2010) stopping power data, respectively, and a straight projectile is assumed.
(A) Energy deposited (eV) in 1-nm-thick spherical shells as a function of radius (µm) from a point source. The energy-deposition profiles exhibit sinusoidal behavior,
apart from the α-emitter 211At, due to AE emitted from different atomic shells being stopped at different distances. β-emitters (67Cu, 153Sm, 161Tb, and 177Lu)
eventually overtake the AE-emitters after 10 µm from the point source. 211At deposits at least an order of magnitude higher energy than other radionuclides for the
entire range considered. Its energy-deposition profile is fairly constant from 0.3 µm, where all recoiling daughters are stopped, up to about 30 µm where some
α-particles emitted from 211At start to slow down and eventually come to a halt around 50 µm. (B–D) Absorbed dose in spherical volumes per cumulated activity
(Gy/Bq/s) as a function of diameter (µm) with a point source at the center. AE-emitters deposit significantly more dose than β-emitters that have a small AE
contribution (67Cu and 177Lu) in organelles with diameter less than 1 µm. For volumes bigger than a cell, β-emitters are more suitable in delivering the desired dose
over the entire region. This highlights the need for AE-emitters to be targeted to radiosensitive subcellular organelles for the anticipated therapeutic efficacy. Although
161Tb is a β-emitter, its decay involves a significant contribution of AE so subcellular targeting using this radionuclide would enhance its radiobiological effect. The
dose-deposition profile of 211At shows that it delivers a significantly higher physical dose to a spherical volume of diameter less than 100 µm than the other
radionuclides considered.
METHODS TO DETECT THE SPATIAL
DISTRIBUTION OF RADIONUCLIDES
To evaluate the potential efficacy of a novel radionuclide
therapeutic, it is essential to obtain information about the spatial
distribution and radiation dose deposition in relevant tissues
and cells. One of the major advantages of TRT is the ability to
visualize drug distribution and tumor targeting in patients by
means of PET or SPECT. Isotopes such as 99mTc, 111In, and 123I
were initially used for diagnostic purposes due to the emission
of γ-rays, and only later considered as potential therapeutics as
a result of the AE-emitting effects (Gomes et al., 2011). Cellular
targeting was mainly directed to membrane receptors, because
of their abundant expression and relative accessibility. However,
the majority of potential cancer cell targets reside intracellularly
(Cornelissen, 2014). Specific subcellular targeting of theranostic
probes may therefore not only have an impact on cancer cell kill,
but also on imaging. Several techniques have been described to
elucidate the subcellular distribution of radionuclides (Puncher
and Blower, 1994; Falzone et al., 2012; Mather, 2012; Kim
et al., 2017). This section reviews the different techniques and
provides a summary of the main advantages and limitations
(Table 2).
Fractionation Assays
One of the most commonly employed methods to determine the
localization of radionuclides on a subcellular level is the use of
fractionation protocols for isolation of subcellular components.
A gamma-counter is then used to detect and quantify the
amount of radioactivity associated with each fraction. Cells
may be disrupted by osmotic shock, ultrasonic vibration,
lyzed in a blender, or extruded through a fine needle. These
procedures are detrimental to cell membrane integrity, including
the endoplasmic reticulum (ER) and plasma membrane, but
leave important organelles such as the nucleus, mitochondria,
peroxisomes, and lysosomes largely intact. Organelles each have
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TABLE 2 | Advantages and disadvantages of subcellular localization techniques for radionuclide therapy.
Methods Radionuclides Advantages Disadvantages
Fractionation assay γ-emitters Quantitative Disruptive
Ease of use No spatial information
Required time (2–3 days) Does not take population variation into account
EM-MAR AE-emitters High spatial resolution Fixed cells
Semi-quantitative High rate and ease of artifact production
Non-linear signal due to silver bromide crystal
saturation
Required time (1.5–3 weeks)
Specialist handling required
PAR AE-emitters High spatial resolution (∼10 nm)
Semi-quantitative
Fixed cells
Lithography process can lead to
over-development
NanoSIMS All isotopes High spatial resolution
Quantitative





Radioluminescence β- and positron-emitters Potential of live cell imaging Low throughput (∼100 cells/acquisition)
Moderate spatial resolution Long acquisition times (15–30 min)
Highly sensitive (<1 attomole)
Quantitative
α-camera α-emitters Quantitative Low resolution (∼35 µm)
Requires collimation
Timepix α-, β-, γ-, and
muon-emitters
Quantitative
Suitable for a variety of radionuclides
Low resolution (∼77 µm)
a distinctive size, charge, and density, and the homogenate can
therefore be separated by centrifugation steps in different buffers
(Alberts et al., 2002). When these fractions are separated, and the
radioactive content is measured using a γ-counter, it is possible to
obtain a highly quantitative measure of the relative uptake of the
radionuclide in each type of organelle. Several researchers have
reported the use of this approach, including Chen et al. (2006),
Zereshkian et al. (2014), and Ngo Ndjock Mbong et al. (2015).
This technique can be used for all γ-emitting radionuclides,
making it a highly useful technique in TRT research. Although
this technique is excellent for describing the average intracellular
distribution of radioactivity for cell populations, detailed spatial
information is lost. Furthermore, fractionation and gamma-
counting provide a population average distribution and do not
take into account the large variation of uptake between individual
cells.
Microautoradiography
Microautoradiography is a technique that involves the use of
X-ray films, beta imaging systems, phosphor imaging plates, or
a photo-nuclear emulsion to detect radiolabeled molecules. It
can be used to visualize and quantitatively resolve compounds
in tissue, cells, and subcellular organelles (Solon, 2015). Two
techniques are of particular relevance to the study of the
localization of radiolabeled drugs to subcellular structures:
electron microscopy – microautoradiography (EM-MAR) (Paul
et al., 1970) and photoresist autoradiography (PAR; Falzone et al.,
2011).
Electron Microscopy – Microautoradiography
EM-MAR is a technique that was reported soon after the
development of the electron microscope by Liquier-Milward
(1956), enabling visualization of the subcellular distribution of
short track-length particulate radiation, such as AE. EM-MAR
involves the exposure of cultured cells or excised tissues to
radiolabeled compounds followed by preparation of the material
for transmission EM. After mounting sections on copper grids,
a fine-grain silver bromide photographic emulsion is applied in
a dark room. The silver bromide crystals in the emulsion may
be reduced by the radiation, and after exposure for a suitable
length of time, the grids are developed photographically, resulting
in transformation of reduced crystals into small black grains.
The position of these grains corresponds with the localization
of the radiolabeled drugs within the original sample and can
give a quantitative image when measured with an EM. The
high spatial resolution of the microscope provides an excellent
means of imaging radionuclides in subcellular compartments
(Solon, 2015). Rind et al. (2005) used this technique to measure
the fate of retrograde-transport of 125I-labeled trophic factors
in neonatal rat hypoglossal motoneurons, and were able to
visualize individual grains in endosomes, lysosomes and the
Golgi apparatus (Figure 2). Grain formation occurs when the
emulsion comes into contact with AE, and can therefore be
used with AE-emitting radionuclides, such as 111In, 125I, and
67Ga (Puncher and Blower, 1994). Despite the advantages, the
technique is used only rarely, which can be attributed mainly to
the long processing time (up to several weeks), the appearance of
silver grain artifacts that complicate interpretation of results, and
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FIGURE 2 | Electron microscopy – microautoradiography of radionuclides in
subcellular compartments. EM-MAR images of hypoglossal motoneurons
treated with 125 I-labeled retrogradely transported trophic factors. The location
of the radionuclide is revealed by the formation of silver grains. (A) 125 I-labeled
glial cell line-derived neurotrophic factor (GDNF) in a light endosome (arrow).
(B) 125 I-labeled brain-derived neurotrophic factor (BDNF) in a dense
endosome (arrow). (C) 125 I-labeled CT-1 in a lysosome (arrow).
(D) 125 I-labeled GDNF in a heavily labeled multivesicular body (MVB).
(E) 125 I-labeled GDNF in the endoplasmic reticulum. (F) 125 I-labeled GDNF in
the Golgi apparatus with Golgi (G)-associated vesicles (arrows). Scale bars
represent 500 nm. Source: Rind et al. (2005). Reproduced with permission
from the Journal of Neuroscience. Copyright: Society of Neuroscience.
the difficult and highly specialized techniques needed to develop
the TEM grids (Solon, 2015).
Photoresist Autoradiography
Recently we have developed an autoradiographic technique, PAR
(Falzone et al., 2011, 2012; Royle et al., 2015, 2016), based
on photoresist lithography that has its origin in integrated
electronics (Figure 3; del Campo and Arzt, 2008). This type
of lithography is based on the exposure of a photosensitive
polymer to AE-emitting radionuclides - vector conjugates, such
as 111In-hEGF, which results in the pattern of distribution
of the radionuclide being etched onto a polymer film (Royle
et al., 2015). An atomic force microscope (AFM) is used
to read the 3D-pattern in the resist, which can be used to
determine the radiation dose and localization on a single-
cell or subcellular level. The spatial resolution is higher than
micro-autoradiography, providing an opportunity to quantify
radionuclide distribution on a nanometer scale. This detailed
spatial information allows a nanoscale radiation absorbed
dose map to be generated. A typical experiment involves
the exposure of cancer cells to a pharmacon radiolabeled
using an AE-emitting isotope. Post-exposure, the cells are
washed and air dried. An inverted photoresist is placed
directly on top of the cells and incubated for a time roughly
equivalent to four half-lives of the specific radionuclide under
investigation, allowing the emitted AE to produce spatially-
resolved images in poly(methyl methacrylate) (PMMA). The
images are converted to a pattern of pits after chemical
development, which can be measured following acquisition of
AFM images.
Nanoscale Secondary Ion Mass
Spectrometry
Nanoscale secondary ion mass spectrometry (NanoSIMS) is a
recent development in SIMS technology that is used to image
the spatial distribution of elements, such as radionuclides, in
biological and non-biological samples. NanoSIMS combines
the simultaneous detection of heavy and light elements with
an excellent spatial resolution (50 nm; Wedlock et al., 2013).
A detailed description of the technique is given by others (Jiang
et al., 2016; Nuñez et al., 2017). Briefly, in this technique, a
high-energy ion beam (Cs+) is directed across the cell sample
surface, causing atom sputtering from the topmost monolayers
and resulting in the generation of negative secondary ions. These
ions are mass sorted and used to produce a map of the sample
surface, which shows the distribution of selected ion species. The
images are produced in parallel from the same sputtered volume,
allowing them to be in exact register with each other, which is
necessary for acquiring quantitative images (Lechene et al., 2006).
Quantitative mass images contain a number of counts at each
pixel for each selected atomic mass, which is directly proportional
to the sample abundance at the specific subcellular location. The
high mass resolution facilitates the simultaneous detection of
the intracellular distribution of multiple isotopes of the same
element, which allows derivation of meaningful isotope ratios. In
the case of radionuclides, a ratio higher than the natural sample
abundance, which is in almost all cases very low, indicates the
subcellular location and the relative excess. The high stability
of primary beam, mass spectrometer, detectors, and ion optics
results in precise measurements of the sample. The ability to
detect stable and radioactive isotopes alike with high resolution
makes this a powerful technique for the identification of the
subcellular distribution of virtually every type of radionuclide
(Lechene et al., 2006). The downsides of the technique are the
costly, specialist, and time-consuming sample preparation, as
well as its ablative nature, meaning that this technique is not
suited for live cell imaging (Gao et al., 2016).
Radioluminescence Microscopy
Radioluminescence microscopy is a recently developed technique
that can provide quantitative measurements of β-emitting
radionuclide transport on the level of a single live cell (Figure 4;
Pratx et al., 2012). Radioluminescence microscopy is based on
the use of a scintillator crystal in close proximity to cells. This
crystal flashes each time a β-particle or positron is emitted from
the underlying cell. The individual flashes can be recorded to
reveal the distribution of radiolabeled probes in single cells. The
technique can be used qualitatively by using a long exposure
(30–300 s) and integrating the optical signals of the many
captured decays into an approximate image, or quantitatively,
by obtaining many camera frames with short exposure (0.01–
0.1 s). The latter requires frame-by-frame processing to extract
the precise location of individual decay events, which can be
digitally counted and created in a composite image (Kim et al.,
2017). This technique has been pioneered by the Pratx group,
who has used it in several applications, including to detect 18F-
fluoro-deoxyglucose (FDG; Pratx et al., 2012) and 64Cu- and
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FIGURE 3 | The photoresist autoradiography method. (A) Electron beam calibration: (i) 5x5 µm2 patterns of varying fluence incident on the PMMA substrate (the
laser reflecting off the AFM probe is shown). (ii) AFM image of 5 µm × 5 µm electron beam feature. (iii) Line scan relating depth to electron fluence. (B) Model system
consisting of 111 In-DTPA radiolabeled microspheres: (i) optical image showing the close packing of the microspheres on the PMMA surface, (ii) AFM contour
through image of a radiolabeled microsphere pattern, and (iii) 3-D generated profile of the AFM feature. (C) Resist exposed to radionuclide treated cells and isolated
cell nuclei, followed by removal of biological material and chemical development of the resist and AFM analysis of the pattern. (D) Demonstration of PAR with
111 In-DTPA-hEGF treated cells: (i) optical image of radionuclide treated SQ20B (head and neck squamous carcinoma) cells, (ii) AFM image of an 111 In-DTPA-hEGF
treated cell pattern, and (iii) 3-D generated plot of an AFM image of a cell nucleus relating local pattern depth to local fluence based on electron beam calibration.
89Zr-labeled rituximab (Natarajan et al., 2015). Although this
technique does not provide the excellent spatial resolution of EM-
MAR, it does provide the opportunity to visualize and quantify
the (sub-) cellular distribution of radionuclides in live cells.
Microdosimeters
The α-camera, first described by Bäck and Jacobsson (2010),
combines autoradiography with a scintillation technique and
optical registration using a charge-coupled device (CCD). It
measures the activity distribution of α-particle emitters with
high resolution (≤35 µm) down to a scale approaching the
cellular level by virtue of the short path lengths of the α-particles.
Furthermore, the pixel intensity is linearly related to the activity,
thus allowing for quantitative analysis of the imaged tissue.
Chouin et al. (2013) used an α-camera for the detection and
measurement of an 211At radioimmunoconjugate that had been
administered to mice with ovarian cancer micrometastases.
α-camera imaging showed high uptake and retention at the
tumor surface and, by measuring the activity level and the
number of tumor cell clusters, it was possible to calculate dose
estimates to the micrometastases.
Another microdosimeter, Timepix, takes advantage of recent
developments in complementary metal–oxide–semiconductor
(CMOS) technology for constructing integrated circuits (Llopart
et al., 2007). Timepix consists of a silicon semiconductor layer,
divided into an array of pixels, which is bumped-bonded to
an electronics integrated layer. Each pixel is connected to
an individual charge-sensitive preamplifier, a discriminator, a
counter, and a 4-bit digital-to-analog converter (DAC) to adjust
the voltage threshold (Llopart et al., 2007; Rügheimer et al., 2008).
Timepix directly measures energy deposition from charged
particles and photons in real time (Campbell et al., 2007). Its
utility in detecting β-particles from a Carbon-14 (14C) sample
showed that Timepix was highly sensitive with a minimum
detectable activity of 0.0077 Bq and with a spatial resolution
of 76.9 µm at full-width at half-maximum (FWHM; Esposito
et al., 2011a,b). In another study, Timepix was used to measure
α-particle emissions in tumor sections from mice treated with
chemotherapy and a radiolabeled DAB4 murine monoclonal
antibody [thorium-227 (227Th)-APOMAB] (Darwish et al.,
2015). Results showed that the α-particle emissions could be
visualized and quantified using the detector (Miller, 2018).
Combining Methods
The radiographic and fractionation techniques described above
can provide valuable insights into the subcellular distribution
of radionuclides in their own right but additional information
may be gained when they are applied in combination. For
example, the spatial pattern of radionuclide deposition within
cells that is derived from EM-MAR can be combined with
radioactivity measurements from fractionation assays to allow
the investigator to generate a precise, quantitative map of
radionuclide distribution. Another option is to combine a
radioactivity-detection assay with a non-radioactive assay, such
as confocal microscopy or NanoSIMS (Rbah-Vidal et al., 2017).
In one example, the spatial resolution of confocal microscopy
Frontiers in Pharmacology | www.frontiersin.org 7 September 2018 | Volume 9 | Article 996
fphar-09-00996 August 31, 2018 Time: 18:35 # 8
Bavelaar et al. Subcellular Targeting of Theranostic Radionuclides
FIGURE 4 | Radioluminescence microscopy. (A) Emission of an intracellular radionuclide can be detected as radioluminescence with a scintillator plate (yellow glow).
The optical photons are captured by a high-numerical-aperture objective coupled to a deep-cooled EM-CCD camera. Concurrent fluorescence and brightfield
microscopy are enabled by emission and excitation filters used in combination with a light source. (B) An in culture medium immersed scintillator plate in a
glass-bottom dish is placed into the inverted microscope. (C) Three GFP-expressing HeLa cells were imaged using fluorescence microscopy. (D) After incubation
with 18F-FDG the focal radioluminescence signal coincided with the fluorescent signal. (E) An example of radioluminescence microscopy. MDA-MB-231 cells were
incubated for 1 h with 18F-FDG and the fluorescent 2-NBDG. Brightfield image (scale bar, 100 µm), radioluminescence (FDG), and fluorescence (2-NBDG)
micrographs. The overlay shows co-localized radioluminescence (green) and fluorescence (red). Source: Pratx et al. (2012). Adapted and reproduced with
permission from PLoS One.
was combined with quantitative fractionation assays to determine
the subcellular distribution of a Cy3- or 111In-labeled probe
targeting γH2AX (Cornelissen et al., 2011). Another example
was reported by Gill et al. (2018), who evaluated the subcellular
localization of 111In-labeled, EGF-tagged, ruthenium-loaded
PLGA nanoparticles through the use of a fractionation assay. By
making use of the metal to ligand charge-transfer (MLCT) “light
switch” properties of the ruthenium compound, which causes a
large increase in photon emission intensity when bound to DNA,
it was possible to show that the majority of the nanoparticles
remained in the cell cytosol while the ruthenium was also found
in the nucleus; a finding confirmed by ICP-MS (inductively




Particulate ionizing radiation can damage biomolecules via
one-electron oxidation reactions, the “direct effect,” or via
the production of ROS, including superoxide radicals (O2−)
and hydrogen peroxide (H2O2), that form the precursors
of damaging hydroxyl radicals (.OH), the “indirect effect”
(Pouget et al., 2015). The primary target for ionizing
radiation is nuclear DNA (Figure 5). Particulate irradiation
of the nucleus can damage the DNA indirectly via water
radiolysis or directly by one-electron oxidation. These
processes can result in DNA single-strand and double-
strand breaks (DSBs), as well as DNA crosslinks and DNA
base damage. If this damage goes unrepaired, cell death
by mitotic catastrophe or apoptosis is triggered (Pouget
et al., 2015). Therefore, to exploit the optimal effect of
TRT, cancer-specific nuclear targeting is of interest to the
research community. Several investigators have developed
approaches to bring radionuclides in close proximity to
cancer cell DNA. Strategies involve direct targeting of the
DNA, sex steroid receptors (SSRs; androgen, estrogen), and
nuclear trafficking cell surface receptors (EGFR, HER2).
Furthermore, subnuclear targeting has been achieved by binding
nuclear proteins (γH2AX, telomerase), and the nucleolus
(Cornelissen, 2014). The following section summarizes recent
advances in the area of targeting subcellular compartments
(Table 3).
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FIGURE 5 | Subcellular targets of Auger electron-emitting theranostic radionuclides. Strategies to reach intracellular targets can broadly be categorized into
radioligands that diffuse through the cell membrane by passive/active transport (1) or bind to cell membrane receptors. Membrane receptor-radioligand complexes
can be internalized via endocytic pathways (2) or remain surface-bound (3), damaging the cell membrane via hydroxyl radical formation (see text for further
explanation). Endocytosed radioligand-receptor can continue to damage endosomes (4), and certain radioligands have the potential to escape endosomal
entrapment (5). Cytosolic radioligands can have various fates and targets. Approaches have utilized radioligands that can bind nuclear proteins, such as γH2AX or
telomerase (6), or that can directly interact with the DNA (7). Some radioligand strategies involve targeting SSR (8), which can traffic to the nucleus of the cancer cell
to exert damage. A more recently explored fate is mitochondrial targeting (9), which can lead to mitochondrial DNA damage and the generation of oxidative stress,
resulting in mitochondrial-induced apoptosis. Endosomal escape can also occur for receptor-radioligand complexes, which can travel to the nucleus, as has been
found with targeting of the EGFR family (10). Most complexes are unable to escape the endosome and will be sorted out of the cell via large endosomal/lysosomal
vesicles. While being processed, radionuclides can continue to do damage endosomal vesicles, and irradiate genomic DNA in case of long track-path radionuclides
emitters, such as 177Lu-/225Ac-PSMA or 177Lu-DOTATATE) (11).
DNA-Binding Agents
Small molecules are able to bind DNA by a range of covalent
and non-covalent binding modes and represent one of the
most heavily studied class of anti-cancer agents. In addition,
many function as fluorescent DNA dyes, and so provide
a convenient means of obtaining intracellular localization
information. The effect of AE-emitters on cell survival was
first studied with molecules that can be incorporated in
to the DNA, such as 125I-UDR. These studies provided
valuable knowledge that illuminated the inverse relationship
between AE-emitter distance to the DNA and DNA damage
and cell kill (Kortylewicz et al., 2012). Since then, several
small molecule DNA intercalators have been proposed as
nuclear-targeting agents for AE-emitting radionuclides, such
as radiolabeled derivatives of acridine orange (Pereira et al.,
2017), pyrene (Häfliger et al., 2005; Reissig et al., 2016),
doxorubicin (Imstepf et al., 2015), and daunorubicin (Fondell
et al., 2011). Acridine orange is a cell-permeable molecule
with anticancer drug and radiosensitizing properties. Pereira
et al. (2017) radiolabeled several analogs with the AE-emitters
99mTc and 125I and demonstrated that both compounds
homed to the nucleus, resulting in an increased number
of DSBs. The Alberto group explored the effect of 99mTc-
labeled pyrene-NLS (SV40 NLS peptide) conjugates on cell
survival and found that these compounds exhibited a DNA
damaging effect, leading to mitotic catastrophe (Haefliger
et al., 2005). Reissig et al. (2016) synthesized related pyrene
constructs with 99mTc-labeled alkyne groups of variable
length. In cell-free studies, they showed a decrease in DNA
damage when the distance between the intercalating moiety
was increased from 0.3 to 1.5 nm, clearly demonstrating
the need for close association with DNA molecules for
AE-generated DNA lesion formation. Similarly, Kotzerke
et al. (2014) radiolabeled DAPI, a dual groove-binder,
intercalator and commonly employed DNA dye, with 99mTc.
In related work, the anthracycline doxorubicin, a widely
used topoisomerase II inhibitor and DNA intercalating
chemotherapeutic, was conjugated to 99mTc to enhance its
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TABLE 3 | Examples of radiopharmaceuticals that target subcellular compartments.
Target Radiolabeled pharmacon Source
Nucleus – DNA 125 I-UDR Kortylewicz et al., 2012
125 I- and 99mTc-labeled acridine orange derivatives Pereira et al., 2017
99mTc-labeled pyrene derivates Häfliger et al., 2005; Reissig et al.,
2016
99mTc-labeled doxorubicin Imstepf et al., 2015
125 I-labeled daunarubicin in HER2-targeted liposomes Fondell et al., 2011
99mTc-labeled DAPI Kotzerke et al., 2014
125 I- and 111 In-labeled TFOs Dahmen and Kriehuber, 2012;
Dahmen et al., 2016, 2017
Nucleus – nuclear
proteins
111 In-labeled anti-γH2AX antibody Cornelissen et al., 2012, 2013
123 I-MST-312 Waghorn et al., 2017
Nucleus – SSRs 123 I-labeled estrogen analogs DeSombre et al., 1992, 2000
123 I-, 125 I-, and 131 I-labeled diethylstilbestrol Fischer et al., 2008
111 In-labeled LXXLL−based peptide Vultos et al., 2017








111 In-labeled nimotuzumab Fasih et al., 2012
111 In-labeled hEGF Cai and Chen, 2008; Vallis et al.,
2014
67Ga-,111 In- and 125 I-labeled MNT targeting EGFR, folate
or melanocortin receptor
Slastnikova et al., 2012, 2017a,b;
Koumarianou et al., 2014
125 I-labeled monoclonal antibody 425 Quang and Brady, 2004
111 In-trastuzumab Costantini et al., 2007, 2008
Methotrexate-loaded BCM conjugated to 111 In, an NLS,
and trastuzumab Fab fragments
Hoang et al., 2012
131 I-labeled anti-HER2 nanobody D’Huyvetter et al., 2017
125 I-,131 I-labeled anti-HER2 nanobody Pruszynski et al., 2014
177 I-labeled anti-HER2 nanobody D’Huyvetter et al., 2012
Mitochondria 177Lu−porphyrin−PEG nanocomplexes Yu et al., 2018
99mTc-HMPAO (speculative) Maucksch et al., 2016
Cell membrane 125 I-labeled anti-CEA monoclonal antibody Pouget et al., 2008; Santoro et al.,
2009; Paillas et al., 2016
Endosomes 177Lu-PSMA-617 Rahbar et al., 2017
225Ac-PSMA-617 Kratochwil et al., 2018
225Ac-PSMA lipid vesicles Zhu et al., 2016
211At-YC-I-27 Kiess et al., 2016
125 I-DCIBzL Kiess et al., 2015
177Lu-DOTATATE Strosberg et al., 2017
potency and diagnostic potential (Imstepf et al., 2015). It
was shown that the conjugate was readily taken up by the
nucleus, caused extensive DNA damage, and exhibited a
dose-dependent reduction in cell survival in several cancer
cell lines. Further characterization with SPECT in nude
mice revealed that 99mTc-labeled doxorubicin had a similar
pharmacokinetic profile as unlabeled doxorubicin, but no
further in vivo efficacy studies were performed. Fondell
et al. (2011) developed an 125I-labeled variant of another
anthracycline, daunorubicin, and encapsulated it in HER2-
targeting liposomes. This dual delivery formulation, in which
HER2 targeting is used for cancer-specificity and DNA
targeting to bring the AE-emitter in close proximity to its
target, resulted in a high cellular uptake and significant
dose-dependent reduction in cellular survival. An additional
option that has been explored for targeting of cancer cell
DNA is the use of triplex forming oligonucleotides (TFO),
site-specific molecules that bind to the major groove of duplex
DNA to form a triplex helix. Several studies by Dahmen
and Kriehuber (2012) and Dahmen et al. (2016, 2017)
have demonstrated that TFOs can be readily labeled with
radionuclides, such as 125I and 111In, and that these conjugates
can exert site- and sequence-specific DNA damage in cancer
cells.
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Nuclear Protein Targeting Agents
The nucleus not only contains DNA, but also harbors many
proteins that are essential for genome expression and integrity
(Cornelissen, 2014). Targeting these proteins can be exploited
in TRT. One example is the development of an 111In-labeled
antibody against γH2AX, the phosphorylated product of H2AX
that forms high density foci around DNA DSBs. Cornelissen
et al. (2012, 2013) demonstrated that conjugation of anti-γH2AX
to the cell penetrating peptide, Tat, which is derived from
the human immunodeficiency virus and contains a nuclear
localizing sequence (NLS), led to increased cellular and nuclear
uptake compared to non-modified antibody. Enhanced uptake
of the radiolabeled Tat-modified antibody resulted in a dose-
dependent reduction in clonogenic survival. Inhibition of tumor
growth was seen in xenograft-bearing mice, in particular
when the tumor was pre-treated with external beam radiation
to induce intratumoral γH2AX expression. Furthermore, the
difference in uptake between tumor and normal tissue was
high enough to visualize the tumor site by SPECT, indicating
the potential of this radioimmunoconjugate as a theranostic.
Waghorn et al. (2017) reported the use of 123I-labeled small
molecule inhibitors of telomerase, a ribonucleoprotein involved
in telomere lengthening and cancer cell immortality. It was
shown that 123I-MST-312, a derivate of the flavonoid epicatechin,
inhibited telomerase and had a favorable uptake and nuclear
distribution pattern, which resulted in a telomerase- and
radioactive dose-dependent reduction in clonogenic survival
after 24 h of treatment.
Sex Steroid Receptor Targeting Agents
Sex steroid receptors are a subclass of steroid hormone
receptors that bind androgens, estrogens, and progestogens.
SSRs play a pivotal role in the development and progression
of malignancies, such as prostate cancer [androgen receptor
(AR; Heinlein and Chang, 2004), and breast cancer (estrogen
receptor (ER)/progesterone receptor (PR; Brisken, 2013; Turner
et al., 2017]. Natural ligands of SSRs pass the cell membrane
by simple or facilitated diffusion due to their lipophilic nature.
Once the molecules are internalized, they associate with receptors
in the cytosol or nucleus, following which these receptor–
ligand complexes act as transcription factors for various genes.
Because of their nuclear localization, SSRs have been exploited
as targets for therapy with AE-emitters (Aranda and Pascual,
2001). An early experiment was conducted by DeSombre et al.
(1992), who showed that 123I-labeled estrogen analogs result in
a significant reduction in clonogenic survival of ER expressing
cells. DeSombre and others subsequently evaluated various
radiolabeled agents for the treatment of cancer, including 123I-
and 111In-labeled analogs of estrogen and diethylstilboestrol, a
non-steroid ER agonist (DeSombre et al., 2000; Yasui et al.,
2001; Fischer et al., 2008; Vultos et al., 2017). Kortylewicz et al.
(2012) developed an interesting hybrid molecule that exploits
dual AR targeting and S-phase specific cell kill by linking
5α-dihydrotestosterone with 5-radioiodo-2′-deoxyuridine. They
showed that this drug is initially trapped in the cytoplasm but
associates exclusively with nuclear DNA after 24 h. A relatively
low dose of radioactivity resulted in a reduction in clonogenic
survival dependent on the expression of AR (Kortylewicz et al.,
2012; Han et al., 2014).
Trafficking Cell Surface Receptor Targeting Agents
Another approach to DNA targeting is to use the nuclear
trafficking properties of cell surface receptors. Although not a
dominant internalization pathway, several cell surface receptors
translocate to the nucleus upon ligand binding where they can
act as transcription factors. Of particular interest are members
of the human epidermal growth factor receptor (EGFR) family
that contain NLS in the transmembrane region. Researchers,
in particular the Reilly group, have exploited this concept for
the nuclear targeting of AE-emitters (Aghevlian et al., 2017).
The most prominently exploited target is EGFR, which is
frequently overexpressed in cancer and associated with poor
prognosis. Non-canonical nuclear trafficking of the receptor
results in the activation of cyclin D1 and NOS, a function
that is enabled by its NLS (RRRHIVRKRTLLR; Wang et al.,
2010). Researchers have shown efficient cellular and nuclear
uptake of 111In-labeled anti-EGFR immunoconjugates with and
without NLS-conjugation, which resulted in effective cell kill and
localization at the tumor site as visualized by SPECT in EGFR-
overexpressing breast cancer MDA-MB-468 xenografts (Fasih
et al., 2012). A similar effect was seen for 111In-labeled hEGF,
that caused toxicity in cells that expressed a high number of
EGFR, but not in cells with a low number of EGFR (Cai et al.,
2008). Both antibody (Quang and Brady, 2004) and peptide
(Vallis et al., 2014) EGFR-targeting vectors have been progressed
into Phase I clinical trials, and showed the capacity to home to
the tumor. This topic has been recently reviewed by Aghevlian
et al. (2017). Recently, researchers have tried to further increase
nuclear localization by nanoparticulate approaches, such as gold
nanoparticles (Song et al., 2016) and modular nanotransporters
(MNTs; Koumarianou et al., 2014). The latter strategy utilized
an ingenious nanosystem, developed by Gilyazova et al. (2006),
consisting of the translocation domain of diphtheria toxin
(endosome escape module), an Escherichia coli hemoglobin-
like protein (carrier module), an SV40 large T-antigen NLS
peptide (nuclear import), and hEGF (ligand module), and
the construct was labeled with 67Ga. They showed superior
uptake and cytotoxicity over 67Ga-hEGF, which was attributed
to improved nuclear retention. This MNT has been used with
various other ligand modules (melanocortin receptor and folate
receptor ligands) and radionuclides (111In, 125I) (Slastnikova
et al., 2012, 2017a,b), and has recently been reviewed by Sobolev
(2018).
A second member of the EGFR family, human EGF receptor
2 (HER2), has also been explored as a radio-theranostic target.
HER2 is internalized relatively slowly and transported to the
nucleus upon binding of ligands such as trastuzumab due to
its NLS (KRRQQKIRKYTMRR; Giri et al., 2005). The Reilly
group has extensively exploited this mechanism in combination
with AE-emitter 111In (Costantini et al., 2007, 2008). They
showed that 111In-trastuzumab elicited significant induction of
DNA DSBs and a marked reduction of clonogenic survival.
The group also exploited other vectors, such as methotrexate-
loaded block copolymer micelles (BCMs) conjugated to 111In,
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an NLS (CGYGPKKKRKVGG), and trastuzumab Fab fragments.
Importantly, they showed that NLS conjugation resulted in a
significant increase in nuclear uptake, which led to an improved
anti-proliferative effect in comparison to BCMs without NLS,
highlighting the importance of subcellular targeting of AE-
emitters (Hoang et al., 2012). Studies by D’Huyvetter et al.
(2012, 2014, 2017) and Pruszynski et al. (2014) focused on
the development of nanobodies, Camelidiae derived antibody
fragments that are stable, small, and exceptionally specific for
their target, HER2. The researchers have labeled these nanobodies
with various radionuclides, including 125I, 131I, or 177Lu. It was
shown that 131I-labeled nanobodies have potential as theranostics
by HER2-specific cancer cell binding and internalization,
resulting in a significant extension of the median survival in
BT474/M1 tumor xenografted mice (D’Huyvetter et al., 2017).
Mitochondria
Although the current paradigm in radiobiology posits that
nuclear DNA is the primary target for ionizing radiation,
recent studies provide evidence that extranuclear radiation
can have detrimental effects on cell viability as well. The
mitochondria have emerged as an interesting but relatively
understudied extranuclear target. Circular mitochondrial DNA,
like genomic DNA, is sensitive to the ionizing radiation-induced
damage. Besides this, some investigators have suggested that
ionizing radiation can alter mitochondrial function, induce
mitochondrial oxidative stress, and cause mitochondrial-induced
apoptosis (Kam and Banati, 2013). An elegant study by Yu
et al. (2018) demonstrated this concept with mitochondria-
targeting 177Lu−porphyrin−PEG nanocomplexes. It was shown
that these nanoconstructs, containing the radionuclide 177Lu and
a photosensitizer, caused an increase in ROS and a reduction in
cell viability, in particular when combined with photodynamic
therapy. The treatment with and without photodynamic therapy
also resulted in a significant tumor growth reduction. Other
researchers, such as Maucksch et al. (2016), found indirect
evidence of such an effect. They compared the radiotoxicity of
three 99mTc-labeled pharmacons with differences in subcellular
distribution and found that clonogenic survival was not
exclusively determined by the DNA DSB response. They therefore
speculated that the observed difference in clonogenic survival
of three vectors of 99mTc was the result of a differential
mitochondrial accumulation.
Cell Membrane
Ionizing radiation has detrimental effects on the cell membrane.
Hydroxyl radical molecules that are formed as a result of
irradiation can attack polyunsaturated fatty acid residues
of phospholipids that constitute the cell membrane, leading
to the formation of mutagenic malondialdehyde and 4-
hydroxynonenal. Furthermore, ionizing radiation is known to
activate acid sphingomyelinase, which hydrolyses cell membrane
sphingomyelin to produce phosphoryl choline and ceramide.
Ceramide is a second messenger for cell apoptosis, and essential
for the formation of lipid rafts, which are ceramide-enriched
platforms that contain signaling and transport proteins involved
in MAPK signaling and sustained ROS and reactive nitrogen
species (RNS) production (Pouget et al., 2015). The Pouget
group has published several papers in which they have explored
the concept of radionuclide-induced cell membrane damage
(Pouget et al., 2008; Santoro et al., 2009; Paillas et al., 2016). In
one study, a non-internalizing 125I-labeled monoclonal antibody
against carcinoembryonic antigen (CEA) was compared to
an internalizing antibody against EGFR. It was found that
internalization is not a prerequisite for effective treatment with
AE-emitters in vitro and in vivo, indicating non-DNA targeting
effects (Pouget et al., 2008; Santoro et al., 2009). Paillas et al.
(2016) extended this work and demonstrated that the efficacy
of the 125I-labeled antibody was associated with various factors
involved in or affected by the stability of lipid rafts.
Endosomes and Lysosomes
The targeting of receptor-mediated endocytosis with vectors
directed against cell membrane receptors is a strategy that is
often used in TRT. Binding of an agonist to its receptor can
lead to clathrin-mediated internalization via the formation of
plasma membrane vesicles. These vesicles typically fuse into early
endosomes, and are subsequently sorted to be recycled, degraded
via lysosomes, or modified more specifically in the trans Golgi
network (TGN; Scott et al., 2014; Kaksonen and Roux, 2018).
Internalization of the receptor–agonist complex provides an
opportunity for protracted irradiation of the cell due to retention,
as well as the advantage of being closer to sensitive organelles
such as the nucleus and mitochondria. The construct lifespan in
the endocytic pathway can vary between vectors. For instance,
EGF-EGFR complexes are degraded within 5 h, whereas certain
nanoparticulate formulations can take days (Song et al., 2015;
Dutta et al., 2016). These differences impact the efficacy of the
treatment and should therefore be taken into consideration when
selecting radionuclides with suitable half-lives.
Two extensively researched TRT targets, PSMA and
the somatostatin receptor, exploit this concept. PSMA is a
transmembrane glycoprotein that is frequently overexpressed in
prostate cancer. Various radiolabeled PSMA-binding peptides
and antibodies have been developed for diagnosis and treatment
and have been shown to internalize upon receptor association.
Targeting PSMA with 177Lu-labeled ligands has been particularly
successful in the clinic (Eiber et al., 2017), as it is associated
with relatively few side effects, a high frequency of objective
tumor responses, and a decline in prostate specific antigen
(PSA) level (Rahbar et al., 2017). More recently, it has been
shown that treatment with 225Ac-labeled PSMA-binding
peptide resulted in tumor control in a cohort of 40 patients
(Kratochwil et al., 2018). Interestingly, a study by Zhu et al.
(2016) demonstrated that the internalization pattern of 225Ac-
PSMA could be changed by conjugation of PSMA ligand
to nanovesicles compared to the PSMA ligand alone. It was
found that the nano-conjugated PMSA ligand localized in the
perinuclear region, whereas PSMA ligand itself remained close
to the cell membrane. This perinuclear accumulation translated
into a threefold higher cytotoxicity for a given amount of
internalized radioactivity, indicating the relevance of subcellular
targeting with α-emitters. Other notable examples include the
use of 211At- and 125I-PSMA ligand conjugates, which have
shown tumor growth inhibition in vivo (Kiess et al., 2015,
2016).
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The somatostatin receptor family is upregulated in
neuroendocrine tumors and has been evaluated as a target for
TRT for over 25 years. As for PMSA, the receptor–ligand complex
internalizes upon binding, allowing the payload to irradiate from
inside vesicles and lysosomes. The best characterized compound
is 177Lu-DOTATATE, which has recently shown an impressive
increase in progression-free survival and at 20 months in patients
with mid-gut neuroendocrine tumors in a phase III clinical trial
(65.2% in the 177Lu-DOTATATE group versus 10.8% in the
control group; Strosberg et al., 2017).
Although DNA is viewed as the primary target for the
radiotoxic effects of TRT that bind surface receptor ligands,
their internalization can have effects on other structures,
including components of the endocytic pathway. Lysosomes are
membrane-bound round-spherical vesicles containing hydrolytic
enzymes that break down a variety of molecules. As for the
cell membrane, the phospholipid layer separating the lysosome
content from the cytosol is sensitive to attacks from reactive
hydroxyl radicals. Since the majority of intracellular redox-
active iron resides in lysosomes, H2O2 formation may result
in labile lysosomes that release lytic enzymes and low mass
iron, which can contribute to apoptotic/necrotic death upon
prolonged exposure (Persson et al., 2005).
CONCLUDING REMARKS
A discussion about subcellular targeting for therapeutic
advantage would not be complete without a consideration
of the potential risks associated with unintentional and non-
specific accumulation in normal tissue (Howell, 2011). It is
well documented that the risks associated with low dose and
low dose rate exposures encountered in diagnostic nuclear
medicine are minimal (ICRP, 2007). However, the inherent
risks associated with therapeutic nuclear medicine procedures
are inevitably higher. In this regard, the toxicity of a given
radiopharmaceutical has to be considered on an individual
basis taking into account the dose, dose rate, radiation spectra,
and subcellular distribution. It is evident that the highly non-
uniform distribution of radionuclides among cell populations
has a profound impact on the associated toxicity of a given
radiopharmaceutical and that this effect applies to normal as
well as malignant tissue.
In the past 10 years, the clinical value of TRT has been
demonstrated for the treatment of various cancer indications,
resulting in a 38% increase in their use in the United Kingdom
between 2007 and 2012 (Rojas et al., 2015; Gill et al., 2017).
Given the positive clinical trial results for 177Lu-DOTATATE
and 177Lu-PMSA ligands, the use of TRT in cancer medicine is
likely to expand. This should support development of the clinical
expertise and infrastructure needed for adoption of new agents
into clinical practice. Using radionuclides that are specifically
targeted to subcellular structures can greatly improve the efficacy
and safety of TRT, and may therefore be an attractive avenue to
explore. Many cancer-specific targets reside intracellularly and
opening the potential to target these with TRT is predicted to
provide a welcome opportunity for the treatment and imaging of
cancer.
In this review, we have described the importance of adequate
subcellular targeting, and how novel radiopharmaceuticals can
be characterized according to their distribution in subcellular
compartments. In reality, many drugs will home to several
different organelles, complicating the analysis of which are
the critical targets. The development of novel subcellular TRT
goes hand-in-hand with improvements in techniques to image
and determine their exact cellular localization and mechanism
of action. The techniques highlighted here provide a good
indication of the variation in radionuclide distribution but lack
the option to image and measure the localization and effects in
live cells with high spatial resolution. Efforts aimed to address this
could have far reaching effects for the maturation of the field of
targeted subcellular radionuclide therapy.
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